Court Grants Permanent Injunction For Infringement Of Amgen's Repatha Patents
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St ticks lower as markets monitor Hormuz situation; data awaited
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises 3% as Iran tempers hopes of Hormuz reopening
- Intel stock stumbles following blockbuster $15 billion equity offering
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
Amgen (AMGN) PT Raised to $165 at Baird on Permanent Injunction Win
January 6, 2017 6:16 AM ESTBaird analyst Brian Skorney raised his price target on Amgen (NASDAQ: AMGN) to $165.00 (from $157.00), saying they are incrementally positive on permanent injunction win. The firm maintained a Neutral rating.
Skorney commented, "Amgen continues to rack up wins against Regeneron and Sanofi, with the most... More
